

1730
24.02.23

File No.FDC/MA/22/000066
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

Tele. No.:011-23236965
Fax No. :011-23236973

FDA Bhawan, Kotla Road
New Delhi-110002

Dated:

To,

M/s. Glenmark Pharmaceuticals Ltd., (Unit III),
Village: Kishanpura, Baddi Nalagarh Road,
Tehsil: Baddi, Dist. Solan, Himachal Pradesh-173205.

23 MAY 2023


Subject: Permission to conduct Phase IV clinical trial with the FDC of Glycopyrronium (As Glycopyrrolate IP) 25 mcg + Budesonide IP 400 mcg + Formoterol Fumarate (As Formoterol Fumarate Dihydrate IP) 12 mcg powder for inhalation (in capsule)-regarding -

Dear Sir,

With reference to manufacturing and marketing permission number FDC-MF-85/2022 dated 06.07.2022 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. FDC-CT-06-25/2023 under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

- i. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- ii. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
 - i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
 - ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- iii. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics

- Committee for the protocol for conduct of the clinical trial at the same site; The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- iv. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
 - v. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
 - vi. Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
 - vii. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
 - viii. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
 - ix. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
 - x. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
 - xi. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
 - xii. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
 - xiii. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
 - xiv. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
 - xv. The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
 - xvi. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
 - xvii. The formulation intended to be used in the clinical trial study shall be manufactured under GMP conditions using validated procedures.
 - xviii. It may kindly be noted that merely granting permission to conduct Clinical trials/Bioavailability or Bioequivalence study with the drug does not convey or imply that, based on the Clinical trial data/ Bioavailability or Bioequivalence study data generated with the drug, permission to market this drug in the country will automatically be granted to you.
 - xix. **The follow-up of the study should be up to 06 months.**
 - xx. **The details of last visit including the test parameters should be mentioned at 06 months accordingly.**
 - xxi. **Telephonic follow up should be done at 4th and 5th month of assess the symptom analysis so as to rule out any worsening or exacerbation.**
 - xxii. **The result of Phase IV Clinical Trial Study should be presented before the committee for review**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

Permission no.: **FDC-CT-06-25/2023**

1. The Central Licencing Authority hereby permits **M/s. Glenmark Pharmaceuticals Ltd., (Unit III) Village: Kishanpura, Baddi, Nalagarh Road, Tehsil: Baddi, Dist. Solan, Himachal Pradesh-173205, Telephone no. +911795667200, Fax no. +911795667299** to conduct clinical trial of the new drug or investigational new drug as per protocol number **(GPL/CT/2022/010/IV, version no. 2.0, dated 16.01.2023)** in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 23 MAY 2023

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Glycopyrronium (As Glycopyrrolate IP) 25mcg + Budesonide IP 400mcg + Formoterol Fumarate 12mcg (As Formoterol Fumarate Dihydrate IP) powder for inhalation (in capsule)
Therapeutic class:	Anti-inflammatory, Anticholinergic and Bronchodilator
Dosage form:	Powder for Inhalation (in capsule)
Composition:	Each capsule contains: Glycopyrronium (As Glycopyrrolate IP) 25mcg Budesonide IP 400mcg Formoterol Fumarate 12mcg (As Formoterol Fumarate Dihydrate IP)
Indications:	Indicated as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD)

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A


Central Licencing Authority
Stamp

Dr. RAJEEV SINGH RAGHUVANSHI
Drugs Controller General (India)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
FDA Bhawani, Kotla Road,
New Delhi (India)


Annexure-APermission no.: **FDC-CT-06-25/2023**

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No.
1.	Dr. Anjali R Nath	Citizen Hospital, #14, 2 nd Main, Dispensar Road, Kalasipalya, Bangalore-560002	Citizen Hospital Inst. Ethics Committee, Citizen Wellness LLP, New 14, 2 nd Main Road, Kalasipalya Extn. Bangalore, Bengaluru (Bangalore) Urban Karnataka-560002 ECR/1591/Inst/KA/2021
2.	Dr. Vijay Kumar Bhagwan Barge	Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College and Chhatrapati Pramila Raje General Hospital, Dasara Chowk, Bhausingji Road, Town Hall, Kolhapur, Maharashtra-416002,	Institutional Ethics Committee RCSMGMCIEC2 RCSMGMC and CPR Hospital, Kolhapur, Building No. 2 Quarter No. 3 Room No. 7 Dassara Chowk Kolhapur Maharashtra-416007 ECR/703/Inst/MH/2015/RR-20
3.	Dr. Bharat Mehrota	New Leelamani Hospital, New Leelamani Hospital Pvt. Ltd., 14/116, C-1, Parade Chauraha, Civil Lines, Kanour, UP-208001	Institutional Ethics Committee Leelamani Hospital, New Leelamani Hospital, 14/116 B, C, C-1D, 1 Civil Line Kanpur Kanpur, Kanpur Nagar UP 208001 ECR/1696/Inst/UP/2022
4.	Dr. Saurabh Karmakar	All India Institute of Medical Sciences, Dept. of Pulmonary Medicine AIIMS, Patna Bihhar-801507.	Institutional Ethics Committee IEC-AIIMS-P, All India Institute of Medical Sciences, Patna Phulwarisharif, Patna, Bihar-801507 ECR/1387/Inst/BR/2020
5.	Dr. Amit Bhate	Jeevan Rekha Hospital, Near Nagshanti Motor Showroom, Veer chamber, Opp. Civil Hospital, Dr. B.R Ambedkar Road, Belagavi, 590002.	Institutional Ethics Committee Jeevan Rekha Hospital, Jeevan Rekha Hospital, Dr. B.R. Ambedkar Road Opp Civil Hospital Belagavi, Belagavi (Belgaum), Karnataka-590002. ECR/1242/Inst/KA/2019/RR-22

Place: New Delhi

Date:

23 MAY 2023


Central Licencing Authority
Stamp

Dr. RAJEEV SINGH RAGHUVANSHI
 Drugs Controller General (India)
 Central Drugs Standard Control Organisation
 Directorate General of Health Services
 Ministry of Health & Family Welfare
 Government of India
 FDA Bhawan 1, Koda Road,
 New Delhi (India)

5560/30.05.23

File No. FDC/MA/22/000066

Govt. of India

Tele. No. :011-23236965

Fax No. :011-23236973

Directorate General of Health Services
Central Drug Standard Control Organization
(FDC Division)

FDA Bhawan, Kotla Road
New Delhi-110002

Dated:

To,

M/s. Glenmark Pharmaceuticals Ltd.,
Glenmark House, B2, Mahalaxmi Chambers
22, BhulaBhai Desai Road, Mumbai- 400026

04 AUG 2023

Subject: Amendment in Permission in form CT-06 vide no. FDC-CT-06-22/2023 dated: 24.04.2023 of FDC of Glycopyrrolate IP 9mcg, + Budesonide IP 160mcg + Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 4.8mcg per actuation delivers (ex-actuator) inhalation aerosol & form CT-06 vide no. FDC-CT-06-25/2023 dated: 23.05.2023 of FDC of Glycopyrronium (as Glycopyrrolate IP) 25mcg, + Budesonide IP 400mcg + Formoterol Fumarate (as Formoterol Fumarate Dihydrate IP) 12mcg powder for inhalation (in capsule)-regarding.

Sir,

Please refer to your letter no. FDC/MA/21/000168 & FDC/MA/22/000066 dated 29.05.2022 on the subject matter. This office has issued permission no. FDC-CT-06-22/2023 dated: 24.04.2023 and FDC-CT-06-25/2023 dated: 23.05.2023, the protocol no. is hereby amended as under:

In place of:

Protocol no: GPL/CT/2022/010/IV, version no. 2.0, dated 16.01.2023

Read as:

Protocol no: GPL/CT/2022/010/IV, version no. 3.0, dated 21.04.2023

Please note that other contents and conditions of the said permission shall remain unchanged.

Yours faithfully,


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

